Do the restatements affect Exelon's reported profits or cash flow?

No, the company explicitly states that the restatements do not affect earnings per share, net income, or cash flow for the reported periods. The impact is solely on Other Comprehensive Income, which is a component of Shareholders' Equity.

Where can I find the detailed financial statements for Exelon Corporation?

The detailed financial statements, including statements of income, cash flows, balance sheets, and changes in shareholders' equity, are incorporated by reference into this filing from Exelon's Current Report on Form 8-K/A dated October 30, 2002. Specifically, look for Exhibit 99-1 and Exhibit 99-2 within that report.

What was Exelon's market valuation at the time of this filing?

As of March 1, 2002, the estimated aggregate market value of Exelon's common equity held by non-affiliates was approximately $15.84 billion.

EXC 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Q: What is the primary reason for this amended 10-K filing?

This filing is an amendment to correct accounting entries related to deferred income taxes associated with nuclear decommissioning trust fund securities and to adjust Other Comprehensive Income for equity investments. These adjustments result in a reduction of Other Comprehensive Income by approximately $128 million as of December 31, 2001.

Summary

This 10-K filing from Exelon Corporation, filed on October 31, 2002, is an amendment to their previous filing for the period ended December 31, 2001. The primary purpose of this amendment is to reflect restatements related to accounting for deferred income taxes on nuclear decommissioning trust fund securities and to adjust Other Comprehensive Income for equity investments. Notably, these restatements, totaling approximately $128 million in Other Comprehensive Income reduction as of December 31, 2001, do not impact earnings per share, net income, or cash flow for the reported periods. For investors, the company's substantial market capitalization of over $15.8 billion as of March 1, 2002, and its outstanding share count of approximately 321.4 million shares, indicate its significant presence in the market. The filing heavily references prior reports and incorporated documents for detailed financial statements and selected financial data, suggesting that the core financial performance and condition are to be found in those referenced materials.

Key Highlights

1The filing is an amendment to the 2001 10-K, primarily addressing accounting restatements related to deferred income taxes and Other Comprehensive Income.
2Restatements impacted Other Comprehensive Income by approximately $128 million as of December 31, 2001, but did not affect net income, earnings per share, or cash flow.
3Exelon's market capitalization was substantial, exceeding $15.8 billion as of March 1, 2002.
4The company had approximately 321.4 million shares of common stock outstanding as of March 1, 2002.
5Key financial statements and selected financial data are incorporated by reference from Exelon's Current Report on Form 8-K/A dated October 30, 2002.
6The report details various exhibits including significant agreements, corporate documents, and compensation plans, underscoring the complexity of the company's structure and operations.
7Independent auditors PricewaterhouseCoopers LLP issued an unqualified opinion on the financial statement schedule.

EXELON CORP Annual Report (Amendment), Year Ended Dec 31, 2001

Summary

Key Highlights

Frequently Asked Questions